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threshold may differ in each person, at present, we cannot specify
what distinguishes individuals who develop fatty liver as a result
of alcohol consumption from those who do not.
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Fig. 1. Odds ratio for fatty liver in each category of the average weekly alcohol consumption in men. (A) The odds ratio for fatty liver was analyzed with non-drinkers
as reference and adjusted for smoking status and regular exercise; or (B) analyzed with drinking 0.1–69.9 g/week as reference and adjusted for age, smoking status, and
regular exercise.
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Open acNon-alcoholic fatty liver disease: Severity of ﬁbrosis and its
relationships with clinical and biological variablesTo the Editor:
The paper of Petta et al. [1] throws new light on an important
issue. Indeed, no data were previously available on the impact
of the severity of liver damage on cardiac function and structural
remodeling for patients affected by NAFLD. Moreover, this study
partially clariﬁes the relationship between visceral adiposity and
severe liver ﬁbrosis in these patients. However, some comments
might be useful for a deeper interpretation of these ﬁndings. In
fact, some of our previous work shows that various circulating
molecules (i.e., adiponectin, TGF b1, e-selectin, and endothelin)Journal of Hepatology 20
cess under CC BY-NC-ND license.play a signiﬁcant role in left ventricular remodeling [2,3], pro-
gression of renal function impairment [4,5], and in the manifesta-
tion of left ventricular dysfunction [6–8] in central obese
subjects.
A recent study by Akyildiz et al. [9] found that higher serum
levels of the hormone FGF 21 were associated with larger epicar-
dial fat thickness in obese women. All the above-mentioned
molecules are related to both inﬂammation and ﬁbrosis at var-
ious levels. Thus, these manuscripts could have been discussed
in the paper. Nonetheless, these data will be useful for future15 vol. 62 j 1204–1218
research that want to investigate the complex pathway among
severity of liver damage, visceral obesity, insulin resistance and
cardiac functional and structural abnormalities.
Finally, we have to highlight a crucial inaccuracy in the logis-
tic multivariate analysis. The authors included in the logistic mul-
tivariate model (see Table 2 in original manuscript) two related
variables as visceral obesity (computed from waist circumference
measured in each patient) and epicardial fat thickness. It is wide-
ly known that epicardial fat thickness clearly reﬂects visceral adi-
posity. In particular, Iacobellis et al. [10] demonstrated that waist
circumference is one of the best predictors of epicardial adipose
tissue. So the inclusion of the two variables in the same logistic
predictor model deﬁnes the phenomenon of collinearity. This
event takes place when two or more independent variables are
almost nearly perfectly correlated. When they are used in the
same model as predictors, an important statistical assumption
of the multivariate analysis is violated. Consequently, collinearity
results in uninterpretable and biased parameter estimates and
inﬂated standard errors. The authors ought to have used the term
of abdominal obesity instead of visceral since pericardial fat is
just a measure of the visceral fat. Moreover, abdominal obesity
and epicardial fat thickness variables should never be inputted
as predictors into the model together. On the contrary, only one
of the two variables should be inputted at a time together with
other predictors. Conclusions should be based on suggestions
from adjusted Odds Ratios and their conﬁdence intervals.
This computational mistake could have partially changed the
conclusions and should have been properly considered in both
the results and discussion sections. We hope that these sugges-
tions will be useful for the readers to formulate the right opinion
about these ﬁndings that remain crucial and stimulate further
research in this ﬁeld of liver diseases.
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